



Antibiotics: Reconciling Profit and Sustainable Use

Guest Editor:

Dr. Chantal M. Morel

Faculty of Medicine, University of
Geneva, Rue Michel-Servet 1,
1206 Geneva, Switzerland

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editor

New antibiotics must become a profitable venture for industry if we are to get the new products that we need. However, if we continue to allow sales volumes to directly determine company profits, we should expect continued overuse of these valuable resources and the shorter duration of efficacy that comes with it.

Incentives for stimulating the R&D of new antibiotics are a hot topic right now. Many incentive designs are being put on the table. Some detangle the perverse incentive to maximize sales volumes but others do not. This Special Issue discusses the progress that has been made in this area over the past few years, including from the pilot schemes that have been launched, and in light of the COVID-19 pandemic. Crucially, it also considers the political level to assess how change can be best achieved and where movement is needed next, considering the implications of geographic scope.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)